C4 Therapeutics Inc (CCCC)
4.71
+0.47
(+11.08%)
USD |
NASDAQ |
Jun 24, 16:00
4.705
0.00 (0.00%)
After-Hours: 20:00
C4 Therapeutics Enterprise Value: 65.88M for June 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 24, 2024 | 65.88M |
| June 21, 2024 | 33.54M |
| June 20, 2024 | 20.47M |
| June 18, 2024 | 22.54M |
| June 17, 2024 | 26.66M |
| June 14, 2024 | 43.18M |
| June 13, 2024 | 72.76M |
| June 12, 2024 | 83.08M |
| June 11, 2024 | 76.20M |
| June 10, 2024 | 73.45M |
| June 07, 2024 | 62.44M |
| June 06, 2024 | 66.57M |
| June 05, 2024 | 82.40M |
| June 04, 2024 | 78.96M |
| June 03, 2024 | 74.83M |
| May 31, 2024 | 85.84M |
| May 30, 2024 | 84.46M |
| May 29, 2024 | 85.15M |
| May 28, 2024 | 110.61M |
| May 24, 2024 | 118.86M |
| May 23, 2024 | 125.06M |
| May 22, 2024 | 140.88M |
| May 21, 2024 | 138.13M |
| May 20, 2024 | 128.50M |
| May 17, 2024 | 132.62M |
| Date | Value |
|---|---|
| May 16, 2024 | 152.58M |
| May 15, 2024 | 162.21M |
| May 14, 2024 | 154.64M |
| May 13, 2024 | 166.34M |
| May 10, 2024 | 165.65M |
| May 09, 2024 | 209.69M |
| May 08, 2024 | 185.61M |
| May 07, 2024 | 209.00M |
| May 06, 2024 | 203.49M |
| May 03, 2024 | 205.56M |
| May 02, 2024 | 184.23M |
| May 01, 2024 | 191.80M |
| April 30, 2024 | 175.28M |
| April 29, 2024 | 176.66M |
| April 26, 2024 | 166.34M |
| April 25, 2024 | 171.16M |
| April 24, 2024 | 186.98M |
| April 23, 2024 | 216.57M |
| April 22, 2024 | 213.63M |
| April 19, 2024 | 204.00M |
| April 18, 2024 | 217.07M |
| April 17, 2024 | 214.32M |
| April 16, 2024 | 211.57M |
| April 15, 2024 | 213.63M |
| April 12, 2024 | 251.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-167.91M
Minimum
Sep 27 2023
1.991B
Maximum
Sep 23 2021
555.41M
Average
200.77M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 64.56M |
| AIM ImmunoTech Inc | 13.37M |
| IGC Pharma Inc | 33.81M |
| NovaBay Pharmaceuticals Inc | 2.982M |
| Protalix BioTherapeutics Inc | 66.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.36M |
| Revenue (Quarterly) | 3.039M |
| Total Expenses (Quarterly) | 32.82M |
| EPS Diluted (Quarterly) | -0.41 |
| Profit Margin (Quarterly) | -933.2% |
| Earnings Yield | -50.32% |
| Normalized Earnings Yield | -49.35 |